Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
European Consortium for High-Throughput Research in Rare Kidney Diseases (EURENOMICS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Germany,France,Switzerland,Italy,Netherlands,United States,Türkiye,United Kingdom,Netherlands,United Kingdom,Spain,United Kingdom,Germany,Belgium,Finland,Germany,Germany,Germany,Belgium
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-10-01
End date: 2017-09-30
Duration (months): 60.0
Total project cost (EUR): 15854880.57
EU funding (EUR): 11994567.0
Participants: 29
Project status: CLOSED

EURenOmics will integrate several established consortia devoted to rare kidney diseases with eminent need and potential for diagnostic and therapeutic progress (i.e. steroid resistant nephrotic syndrome, membranous nephropathy, tubulopathies, complement disorders such a haemolytic uraemic syndrome, and congenital kidney malformations). The Consortium has access to the largest clinical cohorts assembled to date (collectively >10,000 patients) with detailed phenotypic information and comprehensive biorepositories containing DNA, blood, urine, amniotic fluid and kidney tissue. The project aims to (1) identify the genetic and epigenetic causes and modifiers of disease and their molecular pathways; (2) define a novel mechanistic disease ontology beyond phenotypical or morphological description; (3) develop innovative technologies allowing rapid diagnostic testing; (4) discover and validate biomarkers of disease activity, prognosis and treatment responses; and (5) develop in vitro and in vivo disease models and apply high-throughput compound library screening. For these purposes we will integrate comprehensive data sets from next generation exome and whole-genome sequencing, ChiP-sequencing, tissue transcriptome and antigen/epitope profiling, and miRNome, proteome/peptidome, and metabolome screening in different body fluids within and across conventional diagnostic categories. These data will be combined in a systems biology approach with high-resolution clinical phenotyping and findings obtained with a large array of established and novel in vitro, ex vivo and in vivo disease models (‘functiomics’) to identify disease-associated genetic variants involved in monogenic or complex genetic transmission, disease-defining molecular signatures, and potential targets for therapeutic intervention. These efforts will converge in the development of innovative diagnostic tools and biomarkers and efficient screening strategies for novel therapeutic agents.

Keywords: kidney,membranous nephropathy,steroid resistant nephrotic syndrome,complement disorders,tubulopathies,renal malformation,exome/whole-genome squencing,proteomics,metabolomics,mirna,chipseq,xenopus
Observational Prolonged Trial In Myotonic dystrophy type 1 to Improve QoL-Standards, a Target Identification Collaboration (OPTIMISTIC)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Netherlands,United Kingdom,Germany,France,United Kingdom,United Kingdom,Germany,United Kingdom,United Kingdom
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-11-01
End date: 2017-04-30
Duration (months): 54.0
Total project cost (EUR): 3851254.07
EU funding (EUR): 3000000.0
Participants: 9
Project status: CLOSED

OPTIMISTIC is a proposal for a European collaborative project of doctors, scientists, relevant stakeholders (TREAT-NMD, patient organizations) and SMEs with the aim to improve clinical practice for patients suffering from a rare, inherited, and neglected disease, myotonic dystrophy type 1 (DM1). It is one of the most variable human diseases with complex, multi-systemic and progressively worsening clinical manifestations. Despite the huge impact of DM1 on the daily life of both patients and their family members, DM1 patients fail to receive the quality of healthcare that is available as they are not assertive users of the health care system. There is no cure for DM1. The aim of treatment is to relieve impairments, reduce limitations and support participation in everyday activities. Based on our DM1-specific model which shows that physical activity and experienced fatigue are main determinants of DM1 health status (Kalkman 2007), OPTIMISTIC investigates the effect of cognitive behavioural therapy (CBT) in combination with exercise training to improve functional capacity and to stimulate an active lifestyle. OPTIMISTIC compares the outcome of a treatment regimen with regular management in a multi-centre, assessor-blinded, randomized controlled trial, designed to 1) result in evidence-based clinical guidelines on exercise and cognitive behavioural therapy in DM1, 2) capture clinically meaningful changes in existing and novel outcome measures, and 3) identify both individual and composite biomarkers as surrogate treatment outcome measures that are reflective of the disease state. There is an urgent need for an European clinical trial infrastructure for DM1. High prioritization of this is required to enhance the speed of clinical development of new putative DM1 therapeutics approaching the market. OPTIMISTIC will provide this and safeguard the rapid uptake of the developed clinical guidelines ensuring improvements in DM1 care and quality of life.

Keywords: myotonic dystrophy,observational trial,exercise training,cognitive behavioural therapy,outcome measure,quality of life,biomarkers,evidence-based clinical guidelines,care
A systems biology approach to RESOLVE the molecular pathology of two hallmarks of patients with metabolic syndrome and its co-morbidities; hypertriglyceridemia and low HDL-cholesterol (RESOLVE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Netherlands,Netherlands,Switzerland,France,Germany,Greece,Germany,Belgium,France,Netherlands,Sweden,Finland
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2013-01-01
End date: 2018-06-30
Duration (months): 66.0
Total project cost (EUR): 13675103.28
EU funding (EUR): 10548374.0
Participants: 14
Project status: CLOSED

Through combining basic pre-clinical and clinical research, network analysis and computational modelling, RESOLVE aims at resolving the disturbed dynamics and mechanisms underlying the high triglyceride (HTG) and low high-density lipoprotein cholesterol (HDL-C) phenotype and insulin resistance in patients with metabolic syndrome (MetS) and its associated co-morbidities (cardiovascular disease, CVD; type 2 diabetes, T2DM; non-alcoholic fatty liver disease, NAFLD). RESOLVE will deliver on 6 specific objectives: i) build a computational model for analyzing the kinetics of plasma lipids, lipoproteins and their interactions with glucose metabolism. ii) apply the iterative systems biology cycle for calibrating, validating and improving the computational model in dedicated studies in mice iii) build, calibrate and validate the computational model for use in humans. iv) analyze – based on model and experimental data – which processes in the murine metabolic network regulate the physiological response to perturbations in lipid, lipoprotein and glucose metabolism and how these interact. v) analyze – based on model and experimental data – which processes in the human metabolic network regulate the physiological response to perturbations in lipid, lipoprotein and glucose metabolism and how these interact vi) use the human model to identify network-based drug targets aimed at restoring the metabolic dyslipidemia and glycemic control in patients with MetS and associated comorbidities. RESOLVE 60-months project will result into a novel strategy for development of therapeutic strategies for MetS patients with T2DM, NAFLD or CVD.

Keywords: systems biology,metabolic syndrome,cardiovascular disease,mathematical modelling,hdl,hypertriglyceridemia,cholesterol,insulin resistance,glucose
Diagnosis and Monitoring of Inflammatory and Arthritic diseases using a COmbined approach Based on Ultrasound, optoacoustic and hyperSpectral imaging (IACOBUS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Germany,Norway,France,Germany,Lithuania,Germany
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2013-01-01
End date: 2016-06-30
Duration (months): 42.0
Total project cost (EUR): 3837268.4
EU funding (EUR): 3046476.0
Participants: 7
Project status: CLOSED

Rheumatoid arthritis (RA) and psoriasis arthritis (PSA) are destructive polyarthritic diseases having high incidence rates worldwide of about 1,5% and 0,5% respectively. Arthritis-related joint destruction leads to disabilities which result in a loss of patient’s quality of life, often include an inability to work and significant costs for healthcare systems. The functional outcome is strongly dependent on the time lag between the onset of the disease and the treatment beginning (ideally < 3-6 months). For early diagnosis allowing to improve the course of this devastating disease, sensitive and accurate diagnostic tools are required. Further, excellent image quality is needed for differentiated diagnosis (osteoarthritis vs RA or PSA) permitting the stratification of patient groups required for enabling a personalized therapeutical approach. Therefore, tools for early, precise and reliable diagnosis being affordable for screenings are of highest importance. Within IACOBUS, we suggest a new multimodal approach combining hyperspectral imaging with ultrasound (US) and optoacoustic (OA) techniques for diagnosis of arthritic diseases in finger joints. The proposed concept will allow the diagnosis and monitoring of arthritis based on imaging of early inflammation-induced hyperperfusion. Hyperspectral overview imaging for identification of suspicious joints will be combined with detailed high-resolution 3D imaging of affected joints (OA/US). Osteochondral information will be provided by high-frequency US while OA imaging will allow the high-sensitivity imaging of microvasculature in inflamed tissue. The consortium consisting of 4 SMEs and 3 academic partners will develop a novel non-invasive image-based diagnostic tool with significantly enhanced sensitivity for early arthritis symptoms and thereby allow to make use of the therapeutical window of opportunities. 50% of the overall project budget will go to SMEs which will ensure the exploitation of the developed platform.

Keywords: optoacoustic imaging,ultrasound,hyperspectral imaging,arthritis,multimodal imaging,personalized diagnosis,treatment monitoring,patient stratification,quantitative imaging
Interferon-beta treatment of acute respiratory distress syndrome (ARDS) (TRAUMAKINE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Finland,United Kingdom,Italy,Italy
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-12-01
End date: 2018-05-31
Duration (months): 66.0
Total project cost (EUR): 7817320.0
EU funding (EUR): 5997278.0
Participants: 5
Project status: CLOSED

This application aims at a European marketing application for an orphan indication of the biopharmaceutical interferon-beta (IFN-beta) (EU3/07/505), to treat acute lunge injury (ALI) and acute respiratory distress syndrome (ARDS). Despite the much improved mechanical ventilation techniques and improved supportive therapies, ARDS kills 35-40 % of the 175.000 annual European patients. This condition has no approved pharmacological treatment in Europe. The applicant, Faron Pharmaceuticals, has recently finished a clinical phase I/II study with ALI/ARDS patients to obtain initial safety and pharmacokinetics for IFN-beta. Moreover, the study demonstrated very significant drop in all cause mortality of the IFN-beta treated patients at the day 28, the only accepted efficacy measurement as the primary end point for the treatment of ALI/ARDS. The pharmacological effect of IFN-beta is based on its ability to increase the de novo synthesis of endothelial cell surface anti-inflammatory molecule CD73, which can locally produce the enzymatic end product adenosine. Adenosine, in turn, increases endothelial barrier function and prevents the key step of ALI/ARDS process – vascular leakage. Faron and its clinical network will conduct a pan-European pivotal phase III study for further safety and pharmacokinetics of IFN-beta. If phase II reduction in all cause mortality of the IFN-beta treated ARDS patients can be replicated in a bigger study, the data would allow a marketing application for European regulatory authorities but also a much improved understanding what clinical parameters and biomarkers can attribute to the outcome of this deadly process in lungs. We also anticipate to harmonize European ARDS treatment and to create ARDS specific analytics for future ARDS diagnosis and treatment efficacy. ARDS patients represent massive cost burden to hospitals, societies and insurance companies. New medication for ALI/ARDS is much hoped and most welcome by intensive care doctors.
Lewis Acidic Borocations: improving Suzuki couplings, Material synthesis, Alkylation and Radical Transformations (LAB-SMART)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Starting grants
Action type: Support for frontier research (ERC)
Panel: Materials and Synthesis
Countries involved: United Kingdom
Call:  (ERC-2012-StG_20111012, 2012)
Start date: 2012-10-01
End date: 2017-09-30
Duration (months): 60.0
Total project cost (EUR): 1267160.5
EU funding (EUR): 1267160.5
Participants: 1
Project status: CLOSED

Carbon-carbon bond formation is arguably the most important reaction in synthetic chemistry, exemplified by the award of five noble prizes. The most recent Nobel prize was awarded for the development of palladium catalysed cross coupling, of which Suzuki cross coupling is the most widely applied version in industry and academia and utilizes organo-boronates (RB(OR)2) as the nucleophilic component. The aims of this project are; (i) to simplify the synthesis of organo-boron compounds that are utilized in (a) Suzuki cross coupling and (b) as boron containing materials for organic electronic applications. (ii) Reduce the dependency on expensive and toxic palladium by a) extending the Friedel Crafts C-C bond forming reaction to broad scope, electrophilic trifluoromethylation and electrophilic arylation (b) generating and applying efficient iron catalysts in an iron analogue of the Suzuki Reaction. To achieve each of our aims we will utilise the unique properties of electrophilic borocations. Previously we have used boro-cations that combine a coordinatively unsaturated and electrophilic boron centre with a ‘masked’ form of a strong base to develop fundamentally new reactivity. These borocations enabled the sequential one pot activation of a substrate by a strong Lewis acid (the boro-cation) and then release of the masked Lewis base for a subsequent step (e.g., deprotonation). This concept of a boron reagent enabling sequential reactivity by subsequent dissociation of a group is a continual theme through this proposal. This property of borocations will be combined with appropriate leaving groups on the nucleophile to tackle the important challenges outlined above. Key to expanding the synthetic utility is design of the borocation to enable the release not only of a neutral Lewis base (for direct borylation, including the synthesis of RB(OR)2) but also an anionic group (for arylation/alkenylation) or a cationic moiety (for alkylation).

Keywords: boron chemistry superacid chemistry
Continuous, highly precise, metal-free polymerisation of PLA using alternative energies for reactive extrusion (INNOREX)

Framework: FP7 — Cooperation
Programme: Nanosciences, Nanotechnologies, Materials and new Production Technologies - NMP
Destination: New production
Action type: Collaborative project
Countries involved: Germany,Belgium,France,Spain,Italy,United Kingdom,Germany,Germany,Germany,Poland,Spain
Call:  (FP7-NMP-2012-SMALL-6, 2012)
Start date: 2012-12-01
End date: 2016-05-31
Duration (months): 42.0
Total project cost (EUR): 4486786.29
EU funding (EUR): 3322715.0
Participants: 12
Project status: CLOSED

The demand for biobased polymers is growing fast. According to the current state of the art, metal-containing catalysts are needed to improve the polymerisation rate of lactones, posing a hazard to health and the environment. InnoREX will develop a novel reactor concept using alternative energies for the continuous, highly precise, metal-free polymerisation of PLA. In InnoREX, metal-containing catalysts will be replaced by organic catalysts. These have been shown to efficiently control the polymerisation of lactide, but their activity must still be improved to meet industrial standards. This will be achieved by the low-intensity but highly-targeted application of alternative energies (microwaves, ultrasound, laser light). These energies increase catalyst activity and enable precise control of the reaction by exciting only small parts of the reaction mixture without response time. To ensure short market entry times commercially well-established co-rotating twin screw extruders will be used as reaction vessels. The reason commercial polymerisations are not yet carried out in twin screw extruders is the short residence time and the static energy input of the extruder, which allows no dynamic control of the reaction. Again, these obstacles will be overcome in InnoREX. The project will utilise the rapid response time of microwaves, ultrasound and laser light to achieve a precisely-controlled and efficient continuous polymerisation of high molecular weight PLA in a twin screw extruder. Additionally, significant energy savings will be achieved by combining polymerisation, compounding and shaping in one production step. For a deepened scientific and engineering understanding of the reaction, the effect of the alternative energies on the reaction kinetics and the potential applications for alternative energies in reactive extrusion, offline chemical and polymer analytics and online characterisation and simulation of the process within the reactor will be carried out.

Keywords: reactive extrusion,pla,continuous polymerisation,organic catalysis,ultrasound,microwave,laser
In vivo pathogen proteome profiling using selected reaction monitoring (PATHOPROT)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Starting grants
Action type: Support for frontier research (ERC)
Panel: Genetics,Genomics,Bioinformatics and Systems Biology
Countries involved: Sweden
Call:  (ERC-2012-StG_20111109, 2012)
Start date: 2013-05-01
End date: 2018-04-30
Duration (months): 60.0
Total project cost (EUR): 1498699.0
EU funding (EUR): 1498699.0
Participants: 1
Project status: CLOSED

Bacterial infections represent a major and global health problem, which is further aggravated by the rapid and ongoing increase in antibiotic resistance. The limited success in the development of targeted therapies for particular invasive strains can be attributed to our limited knowledge how pathogens modulate their proteome homeostasis in vivo, knowledge that has so far remained elusive due to technical limitations. Here I propose the use of proteome-wide selected reaction monitoring mass spectrometry (SRM-MS) for pathogen proteome profiling from samples obtained directly from in vivo using group A streptococci (GAS) as a model system. The proposal describes the use of SRM-MS to facilitate the construction of comprehensive and quantitative molecular anatomy knowledge models outlining spatial organization, pathway organization, absolute protein concentration estimations and interaction partners with host for complete microbial proteomes. Using the molecular anatomy as benchmark I intend compare how the proteome homeostasis is controlled in pathogens isolated directly from patients with different degree of disease severity to understand how disease severity, anatomical location and host dependencies effects the proteome homeostasis. The outlined proposal describes a generic strategy to provide comprehensive understanding of the pathogen adaption directly in vivo and represents a paradigm shift in the field of bacterial infectious disease. This proposal addresses central aspects within the medical microbiology field that has been long sought for but never studied due to technology limitations and will influence the development of the next generation targeted vaccine and therapeutic development programs.

Keywords: proteomics,mass spectrometry,selected reaction monitoring,in vivo,infectious disease,streptococcus pyogenes,host-pathogen interactions,systems biology
Photocatalytic Materials for the Destruction of Recalcitrant Organic Industrial Waste (PCATDES)

Framework: FP7 — Cooperation
Programme: Nanosciences, Nanotechnologies, Materials and new Production Technologies - NMP
Destination: Materials
Action type: Collaborative project
Countries involved: United Kingdom,United Kingdom,Germany,Spain,United Kingdom,Thailand,Malaysia,Viet Nam,United Kingdom,Türkiye
Call:  (FP7-NMP-2012-SMALL-6, 2012)
Start date: 2013-02-01
End date: 2017-01-31
Duration (months): 48.0
Total project cost (EUR): 5148336.61
EU funding (EUR): 3954395.0
Participants: 11
Project status: CLOSED

The project brings together a consortium of EU and ASEAN researchers with the aim of developing a solar powered photocatalytic waste-water treatment system capable of mineralising the recalcitrant organic matter that is not removed by current biological methods. With an emphasis on generating novel materials and new understandings of photocatalytic materials and processes, the interdisciplinary team aims to develop cost effective prototype photocatalytic reactors capable of deployment in remote areas and of treating contaminated water from small scale industrial producers at rates of up to 500 m3 of a day.

Keywords: photocatalysis,waste-water,recalcitrant waste,tio2,band gap,nanostructured sol-gel,core-shell